Search

Your search keyword '"Hicheri, Y"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Hicheri, Y" Remove constraint Author: "Hicheri, Y"
142 results on '"Hicheri, Y"'

Search Results

1. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

2. Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.

9. P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS

10. PB1810: OUTCOME OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANT: A SINGLE INSTITUTION RETROSPECTIVE STUDY

11. P1332: PROMISING OUTCOME OF PATIENTS OLDER THAN 70 YEARS WHO UNDERWENT PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME

16. L’ajout de la lomustine bénéficie aux leucémies myéloïdes aiguës du sujet âgé avec cytogénétique non-défavorable et d’un profil moléculaire à haut risque de l’European Leukemia Net 2017

29. French Intensive Care Society, International congress - Réanimation 2016

31. Prise en charge d’une réactivation/infection à CMV chez l’allogreffé et prise en charge de la réactivation EBV/syndrome lymphoproflifératif à EBV chez l’allogreffé de cellules souches hématopoïétiques

32. Allogreffe de cellules souches hématopoïétiques à partir d’un sang cordon non apparenté : quelle unité choisir ?

37. French Intensive Care Society, International congress – Réanimation 2016

38. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

39. Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.

40. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.

41. Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia.

42. Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.

43. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.

44. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.

45. DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias.

46. Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis.

47. A case of platelet transfusion refractoriness in a CD36-negative patient with acute myeloid leukemia: Diagnostic and therapeutic management.

48. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.

49. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study.

50. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.

Catalog

Books, media, physical & digital resources